The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
The target reach is of more than 30 million young people and caregivers across 21 countries
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
Approval strengthens the company’s growing international anti-infective portfolio
Appointment strengthens Medanta’s pediatric super-specialty and respiratory care services in the Delhi-NCR region.
Doctors highlight rising respiratory risks linked to pollution, seasonal changes, and poor treatment adherence amid increasing asthma burden in India
Marking World Asthma Day 2026, doctors sounded the alarm over a steady surge in respiratory illnesses
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Subscribe To Our Newsletter & Stay Updated